The
IAPAM has enhanced its globally-respected website
(http://www.iapam.com)
with new content on the newest player in the injectables arena:
Xeomin. As part of the IAPAM's commitment to keeping physicians and
patient informed, the Aesthetic Resources pages provide consumers and
doctors with treatment-focused content and timely intelligence on the
aesthetic medicine industry's leading products and procedures.
Las
Vegas, Nevada, USA - March 12, 2013 -- After a 10 month
injunction, Xeomin is again being launched in the US as a treatment
of glabellar lines. Therefore, the IAPAM announces the launch of a
NEW Aesthetic Resources Page on Xeomin
(http://iapam.com/xeomin-incobotulinumtoxina).
This NEW content provides an overview of this new and recently
approved neurotoxin, and is aimed to educate physicians and patients
alike on the pros and cons of this new competitor to botox.
Providing
physicians, their staff and consumers with DYNAMIC CONTENT is the
mission of the International Association for Physicians in Aesthetic
Medicine (IAPAM). Comprised of physicians, business experts,
researchers and communications specialists, the IAPAM Team is driven
to ensure that its website, (IAPAM.com), is the best one-stop
'window' for both physicians new to aesthetic medicine, as well as
seasoned professionals and patients. IAPAM.com
is dedicated to keeping physicians and patients up to date with
ever-changing, relevant information on current clinical treatments,
costs benefits, business improvements, horizon technologies and
global trends in the aesthetic medical arena.
The
new page on Xeomin (http://iapam.com/xeomin-incobotulinumtoxina),
offers an Executive Summary including intelligence such as:
-
The main difference between Xeomin and Botox or Dysport, is that
Xeomin contains just one ingredient: botulinum toxin A.
-
Xeomin is a "naked injectable," meaning that it does not
contain any additives. A benefit of a pure-form injectable is that
the human body is less likely to become resistant to it.
-
Xeomin is the only one of the three (Xeomin, Botox and Dysport) that
does not need to be refrigerated before use, and much much more.
Come
and use the ever-expanding content on the IAPAM's Website. Also,
follow the IAPAM's Executive Director, Jeff Russell, as he provides
timely advice to physicians in his weekly blog
(http://iapam.com/category/iapam-blog)
and subscribe to our Aesthetic Medicine News RSS Feed
(http://feeds.feedburner.com/AestheticMedicineNews)
to receive breaking news about aesthetic medicine advances. If you
have any questions regarding aesthetic medical treatments, new
technologies, new products, or future trends, please contact the
IAPAM at 1-800-219-5108 or visit http://www.iapam.com.
Botox
is a trademark of Allergan, Inc. Dysport is a trademark of Medicis,
Inc. Xeomin is a trademark of Merz Pharmaceuticals LLC.
About
the International Association for Physicians in Aesthetic Medicine
(IAPAM)
The
International Association for Physicians in Aesthetic Medicine is a
voluntary global association of physicians and supporters, which sets
standards for the aesthetic medical profession worldwide. The goal of
the association is to offer education, ethical standards,
credentialing, and member benefits to members around the globe. IAPAM
membership is open to all licensed medical doctors (MDs), doctors of
osteopathic medicine (DOs), physicians assistants (PAs) and nurse
practitioners (NPs). The IAPAM offers aesthetic medicine and hCG
medical weight management programs, including: Botox training,
medical aesthetic training, laser training, physician hCG training,
and aesthetic practice business training. Additional information
about the association can be accessed through the IAPAM's website
(http://www.iapam.com)
or by contacting:
Jeff
Russell, Executive-Director
International
Association for Physicians in Aesthetic Medicine (IAPAM)
1-800-219-5108
x704
No comments:
Post a Comment